SIM0237

DRUG2 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions

Locally Advanced Unresectable or Metastatic Solid TumorNon-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

TerminatedNCT05781360

Jiangsu Simcere Pharmaceutical Co., Ltd.Locally Advanced Unresectable or Metastatic Solid Tumor

Start: 2023-03-08End: 2024-05-25Updated: 2024-12-20

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

RecruitingNCT06186414

Jiangsu Simcere Pharmaceutical Co., Ltd.Non-Muscle-Invasive Bladder Cancer (NMIBC)

Start: 2024-01-23End: 2030-12-31Target: 152Updated: 2025-01-15